Finance entity

CorMedix Inc.

Company CRMD

Every one of those 1 sits in a single category, earnings. CorMedix Inc. is most often covered alongside Acorn Energy, Inc., which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3.

Last mentioned: Mar 6, 2026

Entity pulse

Recent coverage · CorMedix Inc.

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about CorMedix Inc.

Every one of those 1 sits in a single category, earnings. CorMedix Inc. is most often covered alongside Acorn Energy, Inc., which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. CorMedix Inc. appears in 1 tracked Finance story from March 6, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 95 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering CorMedix Inc.. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Earnings Calls

    Management teams for both companies host conference calls to provide strategic updates and 2026 outlook.

  2. Transcript Release

    Full transcripts of the Q4 2025 earnings calls are made available to the public and analysts.

  3. SEC Filings

    Both ACFN and CRMD file 8-K reports detailing Q4 and full-year 2025 financial results.

Stories mentioning CorMedix Inc. 1

Earnings Neutral

Micro-Cap Execution: Acorn Energy and CorMedix Deliver Q4 2025 Results

Acorn Energy and CorMedix both reported Q4 2025 financial results on March 5, 2026, marking a critical transition from development to commercial scaling. While Acorn focuses on high-margin IoT recurring revenue, CorMedix is navigating the complex rollout of its lead product, DefenCath, in the dialysis market.

2 sources

CorMedix Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.